- Home
- PGP vs BDTX Comparison
PGP vs BDTX Comparison
Compare PGP & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PGP | BDTX |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.9M | 116.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PGP | BDTX |
|---|---|---|
| Price | $8.64 | $2.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 40.1K | ★ 527.8K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 10.84% | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.28 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.83 | $1.30 |
| 52 Week High | $9.41 | $4.94 |
Technical Indicators
Market Signals| Indicator | PGP | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.36 | 61.65 |
| Support Level | $8.57 | $2.45 |
| Resistance Level | $8.71 | $2.64 |
| Average True Range (ATR) | 0.20 | 0.13 |
| MACD | 0.07 | 0.05 |
| Stochastic Oscillator | 87.14 | 82.11 |
Price Performance
Historical ComparisonAbout PGP Pimco Global StocksPlus & Income Fund of Beneficial Interest
PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.